Cefaclor Tablets
Function and Efficacy
This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.
Ingredients
(6R,7R)-7-[(R)-2-Amino-2-phenylacetylamino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| CefaclorIngredients |
This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls. More |
53994-73-3 | 29 |
Appearance
This product is a film-coated tablet, which appears white or off-white after removing the coating.
Indication
This product is mainly suitable for respiratory system, urinary system, ENT, skin and soft tissue infections caused by sensitive bacteria.
Usage and Dosage
This product is suitable for oral administration on an empty stomach. The usual dosage for adults is 0.25g (1 tablet) at a time, 3 times a day. In case of severe infection, the dosage can be doubled, but the total amount per day should not exceed 4g (16 tablets), or follow the doctor's advice. Children are generally given 20mg/kg per day according to body weight, divided into 3 times. In severe infection, the dosage can be increased to 40mg/kg, but the total amount per day should not exceed 1g (4 tablets).
Adverse Reactions
1. Nausea, vomiting, diarrhea and abdominal discomfort are more common. 2. Allergic reactions such as rash and drug fever. 3. Nervous system reactions such as dizziness, diplopia, tinnitus, convulsions, etc. 4. Transient renal damage may occasionally occur during the use of this product. 5. Occasionally, patients have elevated serum aminotransferase and positive Coombs test. Hemolytic anemia is rare, and neutropenia and pseudomembranous colitis have also been reported.
Precautions
Patients who are allergic to this product or other cephalosporins are contraindicated.
Special Population Medication
Precautions for children: The efficacy and safety of this product for infants under one month have not been established. Precautions for pregnancy and lactation: Pregnant women: Multiple reproductive studies have been conducted on mice and rats, with doses as high as 12 times the human dose, and the dose of ferret studies was three times the maximum human dose. The results showed that there was no evidence that cefaclor impaired fertility or endangered the fetus. However, there are no adequate and strictly controlled clinical studies on pregnant women. Because animal reproductive studies cannot fully predict the response of the human body, pregnant women should not use this product unless it is necessary. Delivery: The effect of cefaclor on delivery is unclear. Lactating women: After a lactating woman takes 500 mg of cefaclor orally once, a small amount of cefaclor can be detected in breast milk. The average levels at 2.3.4 and 5 hours after taking the drug are 0.18, 0.20, 0.21 and 0.16 mg/L respectively, and trace amounts of drugs are detected in the first hour. The effect of this product on infants is unknown. Be cautious when using cefaclor for lactating women. Elderly precautions: According to literature reports, compared with healthy adult subjects under 45 years old, 40-50% of healthy elderly subjects (over 65 years old) who took 750 mg of cefaclor alone had high AUC, and 20% had low renal clearance. These differences are mainly caused by age-related functional kidney diseases. In clinical studies, when elderly patients take the recommended adult dose, the clinical effect and safety are similar to those of adult patients, and the dose taken by elderly patients is no different. Therefore, unless the elderly patient is weak, malnourished, and has severe renal impairment, there is generally no need to adjust the dose.
Drug Interactions
1. Furosemide, ethacrynic acid, bumetanide and other strong diuretics, carmustine, streptozocin and other antineoplastic drugs and aminoglycoside antibiotics and other nephrotoxic drugs combined with this product may increase nephrotoxicity. 2. Clavulanic acid can enhance the antibacterial activity of this product against certain Gram-negative bacteria that are resistant to this product due to the production of beta-lactamase. 3. Oral administration of probenecid can delay the excretion of this product.
Storage
Keep away from light, seal tightly, and store in a cool, dark and dry place.
Packaging Specification
0.25 g (calculated as C15H14ClN3O4S)
Validity Period
24 months
Manufacturer
Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Guangzhou Baiyunshan Pharmaceutical General
-
Founded in:
1973-07-01 -
Address:
No. 88, Yunxiang Road, Tonghe Street, Baiyun District, Guangzhou -
Tax NO.:
91440101714253245D -
Registered Funds:
- -
Website:
-
Email: